Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
Scalable manufacturing of CAR T cells for cancer immunotherapy
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18
W Glienke, AC Dragon, K Zimmermann… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment
of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus …
of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus …
Modulating tumor physical microenvironment for fueling CAR-T cell therapy
Z Luo, X Yao, M Li, D Fang, Y Fei, Z Cheng, Y Xu… - Advanced drug delivery …, 2022 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy has achieved unprecedented clinical
success against hematologic malignancies. However, the transition of CAR-T cell therapies …
success against hematologic malignancies. However, the transition of CAR-T cell therapies …
Nattokinase-mediated regulation of tumor physical microenvironment to enhance chemotherapy, radiotherapy, and CAR-T therapy of solid tumor
The therapy of solid tumors is always hampered by the intrinsic tumor physical
microenvironment (TPME) featured with compact and rigid extracellular matrix (ECM) …
microenvironment (TPME) featured with compact and rigid extracellular matrix (ECM) …
Non-viral vectors for chimeric antigen receptor immunotherapy
US Tretbar, JG Rurik, EH Rustad, D Sürün… - Nature Reviews …, 2024 - nature.com
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in
haematological malignancies. However, although viral vector-based methods are effective …
haematological malignancies. However, although viral vector-based methods are effective …
[HTML][HTML] Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Despite promising clinical results in a small subset of malignancies, therapies based on
engineered chimeric antigen receptor and T-cell receptor T cells are associated with serious …
engineered chimeric antigen receptor and T-cell receptor T cells are associated with serious …
An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma
R Wang, T Zhu, B Hou, X Huang - Molecular Therapy, 2023 - cell.com
Induced pluripotent stem cells (iPSCs) express a broad spectrum of tumor-associated
antigens and exert prophylactic effects on various tumors. However, some problems remain …
antigens and exert prophylactic effects on various tumors. However, some problems remain …
[HTML][HTML] Powering prescription: Mitochondria as “Living Drugs”–Definition, clinical applications, and industry advancements
Mitochondria's role as engines and beacons of metabolism and determinants of cellular
health is being redefined through their therapeutic application as “Living Drugs”(LDs) …
health is being redefined through their therapeutic application as “Living Drugs”(LDs) …
Dynamics of macrophage tumor infiltration
Long-term remission in cancer patients treated with ex vivo bona fide M1-induced
macrophages has been poor, and the reasons behind this are not understood. Injected M1 …
macrophages has been poor, and the reasons behind this are not understood. Injected M1 …